Biopharm Australia pioneered the worldwide veterinary development of sodium pentosan polysulfate as a disease modifying osteoarthritis drug (DMOAD) under the brand Cartrophen.
Cartrophen Vet (100mg/mL) is approved for dogs and horses in Australia, NZ, Chile and Argentina and for dogs in many countries, including technically demanding jurisdictions such as Japan, France, Germany, Sweden and the UK. Cartrophen Equine (100mg/mL) and Cartrophen Equine Forte (250mg/mL) are approved for horses in Australia and NZ, with Cartrophen Equine Forte also approved in the UAE.
The quality of Cartrophen products is assured by its testing laboratories that are National Association of Testing Authorities, Australia (NATA) accredited and Therapeutic Goods Administration (TGA) licensed.
Founded in Australia in the 1980s, Biopharm Australia is a world leader in the research and development of sulfated polysaccharides for use in veterinary medicine and has ongoing research and development commitments in osteoarthritis, musculoskeletal disease and cancer.